Clinical Trials
21 trialsNCT01908777 2025-10-09
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00020202 2024-03-04
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03534180 2023-10-19
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT00084682 2021-03-05
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed
NCT00426764 2020-02-11
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Phase 2 Completed
NCT01353664 2019-11-25
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
Celgene
Phase 2 Completed
NCT00106301 2019-11-18
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
Celgene
Phase 2 Completed
NCT00106418 2019-11-18
A Research Study for Patients With Prostate Cancer
Celgene
Phase 2 Completed
NCT00106431 2019-10-30
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Celgene
Phase 2 Completed
NCT00106613 2019-10-18
A Research Study for Patients With Metastatic Renal Cell Carcinoma
Celgene
Phase 2 Completed
NCT01822886 2019-10-14
FIL_GEMRO
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT00112463 2017-06-14
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00007345 2017-05-16
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00062075 2015-12-04
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00066638 2015-03-17
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098813 2014-05-28
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00086827 2014-04-10
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077337 2013-06-24
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077194 2013-02-11
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098397 2013-01-24
FR901228 in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00042822 2011-05-17
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed